CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - April 2024
10 Apr 2024: Merck’s $208m acquisition of Abceutics aims to enhance ADC safety
- Merck & Co. acquired UB’s spinout, Abceutics, for $208 million to enhance ADC safety
- The deal included contingent milestone payments and gave Merck access to Abceutics’ payload-binding selectivity enhancer (PBSE) technology
- PBSE technology works to neutralize and stray payload molecules to reduce the impact on healthy cells, may optimize selectivity and efficacy
- In January, Merck acquired Harpoon Therapeutics and its T-cell engagers for $680 million
